BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) announced its participation in several upcoming investor conferences. The company will present at:

• The 22nd Annual Needham Virtual Healthcare Conference on April 19 at 8:45 a.m. ET
• The BofA Securities 2023 Health Care Conference in Las Vegas on May 10 at 6:00 p.m. ET
• The JMP Securities Life Sciences Conference in New York on May 16 at 2:30 p.m. ET
• The RBC Capital Markets Global Healthcare Conference in New York on May 17 at 8:00 a.m. ET

Live audio webcasts and replays will be accessible in the Investors & Media section of BioCryst’s website. Known for developing oral medicines for rare diseases, BioCryst's ORLADEYO (berotralstat) is already approved in the U.S. and other markets.

RESEARCH TRIANGLE PARK, N.C., April 12, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:

• The 22^nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19^th at 8:45 a.m. ET

• The BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10^th at 6:00 p.m. ET

• The JMP Securities Life Sciences Conference in New York on Tuesday, May 16^th at 2:30 p.m. ET

• The RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 17^th at 8:00 a.m. ET
  

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB^® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

 

FAQ

What investor conferences will BioCryst Pharmaceuticals (BCRX) attend in April and May 2023?

BioCryst will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 19, the BofA Securities 2023 Health Care Conference on May 10, the JMP Securities Life Sciences Conference on May 16, and the RBC Capital Markets Global Healthcare Conference on May 17.

Where can I watch BioCryst Pharmaceuticals' presentations from the investor conferences?

You can access live audio webcasts and replays of BioCryst's presentations in the Investors & Media section of their website.

What is the focus of BioCryst Pharmaceuticals' drug development?

BioCryst specializes in discovering novel, oral small-molecule medicines that target rare diseases, particularly where unmet medical needs exist.

What is ORLADEYO and its status in the market?

ORLADEYO (berotralstat) is an oral medication approved in the U.S. and many global markets for treating rare diseases.